Find Selpercatinib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

FDF

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 2152628-33-4, Loxo-292, Retevmo, Selpercatinib [inn], Cegm9ybngd, Selpercatinib [usan]
Molecular Formula
C29H31N7O3
Molecular Weight
525.6  g/mol
InChI Key
XIIOFHFUYBLOLW-UHFFFAOYSA-N
FDA UNII
CEGM9YBNGD

Selpercatinib
Selpercatinib is an orally bioavailable selective inhibitor of wild-type, mutant and fusion products involving the proto-oncogene receptor tyrosine kinase rearranged during transfection (RET), with potential antineoplastic activity. Upon oral administration, selpercatinib selectively binds to and targets wild-type RET as well as various RET mutants and RET-containing fusion products. This results in an inhibition of cell growth of tumors cells that exhibit increased RET activity. In addition, selpercatinib targets, binds to and inhibits vascular endothelial growth factor receptor 1 (VEGFR1) and 3 (VEGFR3), and fibroblast growth factor receptor 1 (FGFR1), 2 (FGFR2), and 3 (FGFR3). RET overexpression, activating mutations, and fusions result in the upregulation and/or overactivation of RET tyrosine kinase activity in various cancer cell types; dysregulation of RET activity plays a key role in the development and progression of these cancers.
Selpercatinib is a Kinase Inhibitor. The mechanism of action of selpercatinib is as a Rearranged during Transfection (RET) Inhibitor, and Cytochrome P450 2C8 Inhibitor, and Cytochrome P450 3A Inhibitor, and P-Glycoprotein Inhibitor, and Breast Cancer Resistance Protein Inhibitor, and Multidrug and Toxin Extrusion Transporter 1 Inhibitor.
1 2D Structure

Selpercatinib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
6-(2-hydroxy-2-methylpropoxy)-4-[6-[6-[(6-methoxypyridin-3-yl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile
2.1.2 InChI
InChI=1S/C29H31N7O3/c1-29(2,37)18-39-24-9-25(28-21(10-30)13-33-36(28)17-24)20-5-6-26(31-12-20)34-15-22-8-23(16-34)35(22)14-19-4-7-27(38-3)32-11-19/h4-7,9,11-13,17,22-23,37H,8,14-16,18H2,1-3H3
2.1.3 InChI Key
XIIOFHFUYBLOLW-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC(C)(COC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CN=C(C=C6)OC)O
2.2 Other Identifiers
2.2.1 UNII
CEGM9YBNGD
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo(3.1.1)heptan-3-yl)pyridin-3-yl)pyrazolo(1,5-a)pyridine-3-carbonitrile

2. Loxo-292

3. Serpercatinib

2.3.2 Depositor-Supplied Synonyms

1. 2152628-33-4

2. Loxo-292

3. Retevmo

4. Selpercatinib [inn]

5. Cegm9ybngd

6. Selpercatinib [usan]

7. Ly3527723

8. Ret Inhibitor Loxo-292

9. Loxo292

10. 6-(2-hydroxy-2-methylpropoxy)-4-[6-[6-[(6-methoxypyridin-3-yl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile

11. 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

12. Ly-3527723

13. 6-(2-hydroxy-2-methylpropoxy)-4-[6-[6-[(6-methoxy-3-pyridinyl)methyl]-3,6-diazabicyclo[3.1.1]hept-3-yl]-3-pyridinyl]pyrazolo[1,5-a]pyridine-3-carbonitrile

14. 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo(3.1.1)heptan-3-yl)pyridin-3-yl)pyrazolo(1,5-a)pyridine-3-carbonitrile

15. Pyrazolo(1,5-a)pyridine-3-carbonitrile, 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxy-3-pyridinyl)methyl)-3,6-diazabicyclo(3.1.1)hept-3-yl)-3-pyridinyl)-

16. Serpercatinib

17. Retevmo (tn)

18. Unii-cegm9ybngd

19. Selpercatinib [mi]

20. Selpercatinib [jan]

21. Loxo-292; Selpercatinib

22. Selpercatinib(loxo-292)

23. Selpercatinib [who-dd]

24. Chembl4559134

25. Schembl20071478

26. Selpercatinib (jan/usan/inn)

27. Gtpl10318

28. Bdbm296429

29. Dtxsid901026442

30. Selpercatinib [orange Book]

31. Bcp29047

32. Cld62833

33. Ex-a2859

34. Nsc818434

35. S8781

36. Who 10967

37. Zb1574

38. Us10112942, Example 163

39. Us10112942, Example 166

40. Us10112942, Example 183

41. Akos037649115

42. Nsc-818434

43. Ac-31588

44. Bs-16622

45. Loxo-292;loxo 292;loxo292

46. Selpercatinib (loxo-292, Arry-192)

47. Example 163 [wo2018071447a1]

48. Hy-114370

49. Cs-0084279

50. D11713

51. D77980

52. A929273

2.4 Create Date
2018-06-23
3 Chemical and Physical Properties
Molecular Weight 525.6 g/mol
Molecular Formula C29H31N7O3
XLogP32.5
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count9
Rotatable Bond Count8
Exact Mass525.24883788 g/mol
Monoisotopic Mass525.24883788 g/mol
Topological Polar Surface Area112 Ų
Heavy Atom Count39
Formal Charge0
Complexity885
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count2
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Selpercatinib is indicated for the treatment of _RET_ fusion-positive non-small cell lung cancer in adult patients. Selpercatinib is also indicated for the systemic treatment of advanced or metastatic _RET_-mutant medullary thyroid cancer and for the systemic treatment of _RET_ fusion-positive radioactive iodine-refractory thyroid cancer in both adult and pediatric patients aged 12 and over. Selpercatinib is currently approved for these indications under an accelerated approval scheme and continued approval may be contingent on future confirmatory trials.


FDA Label


Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue neoplasms)


Retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced RET-mutant medullary thyroid cancer (MTC)

- advanced RET fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor

- advanced RET fusion-positive thyroid cancer who require systematic therapy following prior treatment


5 Pharmacology and Biochemistry
5.1 Pharmacology

Selpercatinib exerts anti-tumour activity in specific cancers through inhibition of mutated forms of RET tyrosine kinases. Due to its increased specificity for RET over other tyrosine kinases, selpercatinib is thought to have an improved safety profile compared to other multi-kinase inhibitors. Despite this, selpercatinib treatment is associated with hepatotoxicity, hypertension, QT interval prolongation, hemorrhagic events, risk of impaired wound healing, and embryo-fetal toxicity; some patients may also exhibit hypersensitivity to selpercatinib.


5.2 FDA Pharmacological Classification
5.2.1 Active Moiety
SELPERCATINIB
5.2.2 FDA UNII
CEGM9YBNGD
5.2.3 Pharmacological Classes
Cytochrome P450 2C8 Inhibitors [MoA]; Cytochrome P450 3A Inhibitors [MoA]; Kinase Inhibitor [EPC]; Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA]; P-Glycoprotein Inhibitors [MoA]; Rearranged during Transfection (RET) Inhibitors [MoA]; Breast Cancer Resistance Protein Inhibitors [MoA]
5.3 ATC Code

L01EX22


L - Antineoplastic and immunomodulating agents

L01 - Antineoplastic agents

L01E - Protein kinase inhibitors

L01EX - Other protein kinase inhibitors

L01EX22 - Selpercatinib


5.4 Absorption, Distribution and Excretion

Absorption

In patients with locally advanced or metastatic solid tumours receiving 160 mg of selpercatinib twice daily, steady-state was achieved after approximately 7 days, with a Cmax of 2,980 (CV 53%) and AUC0-24h of 51,600 (CV 58%). The absolute bioavailability is between 60 and 82% (mean 73%), and the median tmax is two hours. Food has no apparent effect on the AUC or Cmax of selpercatinib. Patients with hepatic impairment display a concomitant increase in AUC0-INF for mild (7%), moderate (32%), and severe (77%) impairment.


Route of Elimination

Selpercatinib administered as a single 160 mg dose in healthy individuals was primarily recovered in feces (69%, 14% unchanged) and urine (24%, 12% unchanged).


Volume of Distribution

Selpercatinib has an apparent volume of distribution of 191 L; the volume of distribution increases with increasing body weight.


Clearance

Selpercatinib has an apparent clearance of 6L/h; the clearance increases with increasing body weight.


5.5 Metabolism/Metabolites

Selpercatinib is predominantly metabolized in the liver by CYP3A4.


5.6 Biological Half-Life

Selpercatinib has a half-life of 32 hours in healthy individuals.


5.7 Mechanism of Action

Rearranged during transfection (RET) is a transmembrane receptor tyrosine kinase containing extracellular, transmembrane, and intracellular domains whose activity is required for normal kidney and nervous system development. Constitutive RET activation is primarily achieved through chromosomal rearrangements producing 5' fusions of dimerizable domains to the 3' _RET_ tyrosine kinase domain, such as _KIF5B-RET_ and _CCDC6-RET_, resulting in constitutive dimerization and subsequent autophosphorylation. Constitutive activation leads to increased downstream signalling and is associated with tumour invasion, migration, and proliferation. Selpercatinib is a direct RET kinase inhibitor, exhibiting IC50 values between 0.92 and 67.8 nM depending on the exact _RET_ genotype. Information based on natural as well as induced resistance mutations and molecular modelling suggests that selpercatinib directly inhibits RET autophosphorylation by competing with ATP for binding. Various single amino acid mutations at position 810 inhibit selpercatinib binding without significantly altering ATP binding, potentially leading to treatment failures. Selpercatinib is also reported to inhibit other tyrosine kinase receptors, including VEGFR1, VEGFR3, FGFR1, FGFR2, and FGFR3, at clinically relevant concentrations. The significance of these effects is not well studied.


Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Selpercatinib Manufacturers

A Selpercatinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Selpercatinib, including repackagers and relabelers. The FDA regulates Selpercatinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Selpercatinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Selpercatinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Selpercatinib Suppliers

A Selpercatinib supplier is an individual or a company that provides Selpercatinib active pharmaceutical ingredient (API) or Selpercatinib finished formulations upon request. The Selpercatinib suppliers may include Selpercatinib API manufacturers, exporters, distributors and traders.

click here to find a list of Selpercatinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Selpercatinib USDMF

A Selpercatinib DMF (Drug Master File) is a document detailing the whole manufacturing process of Selpercatinib active pharmaceutical ingredient (API) in detail. Different forms of Selpercatinib DMFs exist exist since differing nations have different regulations, such as Selpercatinib USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Selpercatinib DMF submitted to regulatory agencies in the US is known as a USDMF. Selpercatinib USDMF includes data on Selpercatinib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Selpercatinib USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Selpercatinib suppliers with USDMF on PharmaCompass.

Selpercatinib NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Selpercatinib as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Selpercatinib API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Selpercatinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Selpercatinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Selpercatinib NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Selpercatinib suppliers with NDC on PharmaCompass.

Selpercatinib GMP

Selpercatinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Selpercatinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Selpercatinib GMP manufacturer or Selpercatinib GMP API supplier for your needs.

Selpercatinib CoA

A Selpercatinib CoA (Certificate of Analysis) is a formal document that attests to Selpercatinib's compliance with Selpercatinib specifications and serves as a tool for batch-level quality control.

Selpercatinib CoA mostly includes findings from lab analyses of a specific batch. For each Selpercatinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Selpercatinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Selpercatinib EP), Selpercatinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Selpercatinib USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty